BioSpace News Archive

WuXi Biologics, a global leading Contract Research, Development and Manufacturing Organization, announced a 10-year USD$1.4 billion investment plan to expand the company’s research, development, and large-scale drug substance and drug product manufacturing capacity and capabilities in Singapore.

he Innovation and Value Initiative (IVI), a non-profit research organization committed to advancing the science, practice, and use of value assessment in health care, today announced the appointment of Jason Spangler , MD, MPH, FACPM as the Innovation and Value Initiative’s next Chief Executive Officer.

Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, announced that it will host a live webcast on Tuesday, August 2, 2022 at 8:00 a.m. ET to announce second quarter 2022 financial results and discuss recent business updates.

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval to LUMRYZ, also known as FT218.

HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases, today announced the appointment of Jose “Pepe” Carmona to its Board of Directors.

One Drop, a leader in precision health solutions for people living with diabetes and other chronic conditions, today announced outcomes from a retrospective cohort study published in the Journal of Medical Internet Research (JMIR) on the effects of its novel AI-powered blood glucose (BG) forecasting feature.

Creative Bio-Peptides, Inc, today announced the publication of findings from a preclinical study showing that treatment with the multi-chemokine receptor antagonist oral peptide RAP-103 substantially reduced heroin self-administration and motivation to consume heroin.

Agiliti Inc. announced that the company will release its second quarter results after the market close on Tuesday, August 9, 2022, to be followed by a conference call at 5 p.m. Eastern Time on the same day.

Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation and Rare Pediatric Disease Designation (RPDD) for WU-CART-007, the company’s off-the-shelf CAR-T cell therapy.

Nascent Biotech, Inc. is pleased to announce that the United States Patent and Trademark Office has issued a Notice of Allowance for claims related to the Company’s lead candidate Pritumumab.